Dr. Atif J. Khan, MD

Dr. Khan practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Khan's NPI, 1255545653, was assigned on May 9, 2007. Dr. Khan graduated from Aga Khan Medical College in 1999. Dr. Khan holds New Jersey license 25MA08267400.

Dr. Khan's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Khan's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is University Neuro-Ophthalmology Associates. Dmand AI also links Dr. Khan to 4 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khan practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Khan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Khan is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Khan's licenses on file in 5 states: New Jersey, Florida, Michigan, New York and Illinois.

Dmand AI lists bone cancer radiation, brain cancer radiation and breast cancer radiation among the conditions Dr. Khan treats.

CMS data shows 1,012 Medicare services from Dr. Khan across 12 procedure codes in 2024, for 386 Medicare patients. Medicare paid $68,528 for them.

CMS counts 386 Medicare patients who saw Dr. Khan in 2024. The largest group is 65 to 74, with 188 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khan's median patient age at 71, with 54% women.

In 2024, Dr. Khan wrote 79 Medicare Part D claims for 55 patients. 92% of them were for generic drugs. CMS names the drug for 49 of them, across 1 drug with 11 or more claims each, at $772 in total drug cost. In 2023, CMS named 36 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Khan for performance year 2024, reported as part of a group. Dr. Khan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Khan as offering telehealth.

Dmand AI links 182 papers to Dr. Khan, published from 2006 to 2025. 2019 was the busiest year, with 20. The most frequent topics are Breast Neoplasms, Mastectomy, Segmental and Radiotherapy, Adjuvant. Dr. Khan has published most often in Int J Radiat Oncol Biol Phys. Dr. Khan's most frequent co-authors are Lior Z. Braunstein, MD, Simon Nicholas Powell, MD, PhD and Bruce G. Haffty, MD.

Dmand AI links Dr. Khan to 7 clinical trials, 3 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Ductal, Breast and Triple Negative Breast Neoplasms. Memorial Sloan Kettering Cancer Center sponsors the most, 7.

CMS Open Payments shows 18 general payments to Dr. Khan from 5 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 84% of the total. Elekta, Inc. paid the most, $2,408.

Dr. Khan graduated from Aga Khan Medical College in 1999.

Dr. Khan is in network with 14 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.